Anebulo Pharmaceuticals Inc (ANEB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.33 (-7.17%), Market cap $0.02B, 52-week low–high $0.33 ~ $3.33.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Financial statements, price targets, institutional (13F) holdings and related news for Anebulo Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Anebulo Pharmaceuticals Inc trades at $0.33 (-7.17%). Real-time quotes and charts are available on BlackAll Trade.
Anebulo Pharmaceuticals Inc has a market cap of about $0.02B.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced